Which Frontline EGFR TKI Should be Used in NSCLC?
Lecia V. Sequist, MD, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.
Adverse Events Associated With CO-1686
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).